| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 05/27/2008 | CA2384111C Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| 05/27/2008 | CA2379752C Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients |
| 05/27/2008 | CA2264895C Device and method for treating ophthalmic diseases |
| 05/27/2008 | CA2256960C High glycerin containing anti-microbial cleansers |
| 05/22/2008 | WO2008059991A1 Diagnosis and treatment of autism using cd38 |
| 05/22/2008 | WO2008059949A1 Knockout animal exhibiting anxiety-like behavior |
| 05/22/2008 | WO2008059261A1 Clotrimazol for treating staphylococcal infections |
| 05/22/2008 | WO2008059258A2 Imidazoles for treating multi-drug resistant bacterial infections |
| 05/22/2008 | WO2008059224A1 Use of buprenorphine or n-alkylated derivatives thereof for wound healing |
| 05/22/2008 | WO2008059197A2 Topical composition comprising an anti- inflammatory steroid and a non-steroidal anti -inflammatory drug |
| 05/22/2008 | WO2008059052A1 Improved methods of using phosphoantigen for the treatment of cancer |
| 05/22/2008 | WO2008059014A2 Antituberculosis agents with alkylidene or alkyl side chain |
| 05/22/2008 | WO2008058383A1 Acat inhibitors and their use in the prevention or treatment of fibrosis |
| 05/22/2008 | WO2008038304A3 Therapeutical formulation comprising an alpha-glucosidase inhibitor and a nitric oxide scavenger. |
| 05/22/2008 | WO2008024734A3 Use of pkc inhibitors in particular indolylmaleimide derivatives in ocular diseases |
| 05/22/2008 | WO2008011726A8 Staged immune-response modulation in oncolytic therapy |
| 05/22/2008 | WO2007124252A3 Combinations of therapeutic agents for treating cancer |
| 05/22/2008 | WO2007120702A3 Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto |
| 05/22/2008 | US20080119571 Transport proteins; lecithin-cholesterol acyltransferase; for increasing circulating high density lipoprotein cholesterol for treating atherosclerosis and related cardiovascular disorders |
| 05/22/2008 | US20080119568 Gastrointestinal Absorption Enhancer Mediated By Proton-Coupled Transporter and Its Preparing Method |
| 05/22/2008 | US20080119561 Methods for preventing or delaying catheter- based resvascularization |
| 05/22/2008 | US20080119529 An epothilone derivative such as epothilone A,B,C or D with a bisphosphonate such as zoledronic acid, a platinum compound such as carboplatin or a vasculostatic compound such as vatalanib succinate; antitumor agents |
| 05/22/2008 | US20080119525 Pyridoxamine for the Treatment of Diabetic Intermediaries and Post-Amadori Inhibition |
| 05/22/2008 | US20080119487 Novel non-imidazole compounds |
| 05/22/2008 | US20080119483 Synergistic combination of lipid synthesis inhibitors; no side effects; itraconazole or ketaconazole |
| 05/22/2008 | US20080119480 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| 05/22/2008 | US20080119455 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase |
| 05/22/2008 | US20080119454 Aryl carbonyl derivatives as therapeutic agents |
| 05/22/2008 | US20080119438 medium molecular weight heparin ranging from 6,000 Daltons to 12,000 Daltons composition, has sufficient length to bridge antithrombin to thrombin, comprising a mixture of sulfated oligosaccharides; treating cardiovascular diseases, preventing the formation of a thrombus, arterial/deep vein thrombosis |
| 05/22/2008 | US20080119434 Sir2a-based therapeutic and prophylactic methods |
| 05/22/2008 | US20080119424 biodrugs contains siRNA or vector encoding siRNA, including a retinoid as antitumor agents, anticarcinogenic agents |
| 05/22/2008 | US20080118560 Spray congealed 5-amido-7-benzyl(oxy or amino)imidazo[1,2-a]pyridines, at least one each of hydrophilic and hydrophobic matrix formers; antisecretory agents with improved water solubility, bioavailability and pharmacokinetics |
| 05/22/2008 | US20080118527 Vaccine comprising hepatitis b viral antigen and hemophilus influenza b protein for use in prevention and treament of viral disease |
| 05/22/2008 | US20080118519 Copper lowering treatment of inflammatory and fibrotic diseases |
| 05/22/2008 | US20080118513 Treatment of immune disorders with antibodies to costimulating polypeptide of T cells |
| 05/22/2008 | US20080118508 Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b |
| 05/22/2008 | US20080118481 Mononuclear phagocytes in therapeutic drug delivery |
| 05/22/2008 | US20080118462 Biomarkers for Melanoma |
| 05/22/2008 | US20080115782 Pressurised metered dose inhalers (mdi) |
| 05/22/2008 | CA2669594A1 Clotrimazol for treating staphylococcal infections |
| 05/22/2008 | CA2669123A1 Acat inhibitors and their use in the prevention or treatment of fibrosis |
| 05/21/2008 | EP1923073A2 Combination medication comprising a PDE-5 inhibitor |
| 05/21/2008 | EP1923072A1 Prophylactic/therapeutic agent for cancer |
| 05/21/2008 | EP1923071A1 Equine herpesvirus vaccine |
| 05/21/2008 | EP1923068A1 System and methods for opening obstructed biological conduits |
| 05/21/2008 | EP1923063A2 Compositions and methods for combination antiviral therapy |
| 05/21/2008 | EP1922077A1 Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment |
| 05/21/2008 | EP1922073A1 New capped pyrazinoylguanidine sodium channel blockers |
| 05/21/2008 | EP1922063A1 Method of treating pain in patients |
| 05/21/2008 | EP1753860A4 Intervertebral disc repair, methods and devices therefor |
| 05/21/2008 | EP1517705B1 Dichloroacetate in combination with cardioprotective or hemodynamic drugs |
| 05/21/2008 | EP1482924B1 Cathepsin cysteine protease inhibitors |
| 05/21/2008 | EP1434773B1 Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| 05/21/2008 | EP1385508B1 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 05/21/2008 | EP1372652B1 Combination of docetaxel and flavopiridol |
| 05/21/2008 | EP1366158B1 Trp8 markers for cancer |
| 05/21/2008 | EP1287130B1 Mammalian cytokine receptor subunit proteins, related reagents and methods |
| 05/21/2008 | EP1261586B1 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase iv, processes for their preparation, and their use |
| 05/21/2008 | EP1161262B1 SURFACE LOCALIZED COLLIGIN/HsP47 IN CARCINOMA CELLS |
| 05/21/2008 | EP1150714B1 Methods for inhibiting brain tumor growth |
| 05/21/2008 | EP1003545B1 Heparin-binding growth factor (hbgf) polypeptides |
| 05/21/2008 | CN101184509A Agent for improvement of insulin resistance |
| 05/21/2008 | CN101184508A Methods of decreasing calcification |
| 05/21/2008 | CN101181639A Medicament for curing ague completely |
| 05/21/2008 | CN101181638A Female surface coating contraceptive |
| 05/21/2008 | CN101181272A Compositions and uses of et743 for treating cancer |
| 05/21/2008 | CN101181269A Methods of treating cancer using an fpt inhibitor and antineoplastic agents |
| 05/21/2008 | CN101181263A Treatment of respiratory diseases |
| 05/21/2008 | CN100389196C Cancer cell vaccine |
| 05/21/2008 | CN100388951C Dietetic food composition and dietetic method using such composition |
| 05/21/2008 | CN100388918C Pharmaceutical compositions based on azetidine derivatives |
| 05/20/2008 | US7375134 N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; osteoporosis and other bone loss disorders |
| 05/20/2008 | US7375118 Phenyl-indole compounds for modulating IgE and Inhibiting cellular proliferation |
| 05/20/2008 | US7375117 Polypeptides |
| 05/20/2008 | US7375106 Analgesic; Ketorolac or indomethacin nsaid with an opioid diarylmethyl piperazine such as 3-[( alpha R)- alpha -((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl]-N-(3-fluorophenyl)-N-methylbenzamide; dosage of the opioid can be decreased so side effects are reduced |
| 05/20/2008 | US7375089 Rehydration composition |
| 05/20/2008 | US7375081 Synergist mixture with lipopeptide and cyclic hexapeptide |
| 05/20/2008 | US7375077 In vivo synthesis of connective tissues |
| 05/20/2008 | US7374894 Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a chloride intracellular channel 1 protein |
| 05/20/2008 | US7374891 Receptor for Advanced Glycated Endproducts (RAGE); detecting binding of ligand and protein in presence of peptide, lipid, carbohydrate; amyloid, high-throughput colorimetric assay |
| 05/20/2008 | US7374772 A mixture comprising triacetin, tolnaftate fungicide and synthetic vitamin A, for treating skin and nail infections, treating patients with immune compromised, or with diabetes, even healthy person |
| 05/20/2008 | US7374769 Method for treating a trigeminal neuralgia by peripheral administration of a neurotoxin |
| 05/20/2008 | US7374765 Methods and compositions for diagnosis and treatment of iron misregulation diseases |
| 05/20/2008 | US7374751 QS-21 and IL-12 as an adjuvant combination |
| 05/20/2008 | US7374747 topical delivery of a quick-breaking temperature sensitive foam antibacterial composition to the skin; clindamycin phosphate and a foaming agent comprising an C1-C6 alcohol, a C14-C22 alcohol, a surfactant, water, aerosol propellant; dispensed from pressurized container; acne |
| 05/20/2008 | CA2611106A1 Anti-coronavirus molecules and their use in compositions and methods for treating and/or preventing infection caused by a coronavirus |
| 05/20/2008 | CA2432223C Pyrazole compounds useful as protein kinase inhibitors |
| 05/20/2008 | CA2416976C Treatment of estrogen receptor positive carcinoma with a rapamycin and an antiestrogen |
| 05/20/2008 | CA2344308C Taurolidine and/or taurultam against infectious ulcer or gastritis |
| 05/20/2008 | CA2333668C 17.beta.-nitro-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 05/20/2008 | CA2294480C Microdose therapy of female sexual dysfunction by no, co, and their donors |
| 05/20/2008 | CA2229202C Methods for identifying antagonist or agonist to human opioid receptor-like 1 "orl1" |
| 05/20/2008 | CA2159610C Prodrugs with enhanced penetration into cells |
| 05/15/2008 | WO2008057562A1 Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer |
| 05/15/2008 | WO2008057503A2 Compositions including triciribine and taxanes and methods of use thereof |
| 05/15/2008 | WO2008057136A1 Oral care compositions containing combinations of anti-bacterial and host-response modulating agents |
| 05/15/2008 | WO2008056391A2 Composition for a pharmaceutical treatment based on triethyl citrate and adapalene |
| 05/15/2008 | WO2008055801A2 Antidiabetogenic calcium-peptide composition |
| 05/15/2008 | WO2008038303A3 Therapeutic formulation comprising a sulfonylurea, a thiazolidinedione and a nitric oxide scavenger. |
| 05/15/2008 | WO2008031820A3 Combinations of class-i specific histone deacetylase inhibitors with proteasome inhibitors |